Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Carol A. Ziomek
Advertisement
Carol A. Ziomek, PhD is vice president for development at GTC Biotherapeutics, Inc.
Articles by Carol A. Ziomek
Advertisement
Latest Updated Articles
Advertisement
Advertisement